Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial

Area of Science:

• Respiratory Medicine
• Pharmacology
• Clinical Trials

Background:

• Severe asthma often persists despite optimal treatment.
• Long-acting inhaled anticholinergics like tiotropium may benefit these patients.

Purpose of the Study:

• To evaluate the efficacy and safety of two tiotropium doses (5 and 10 μg daily) via Respimat inhaler as add-on therapy.
• To compare tiotropium against placebo in severe asthma patients uncontrolled on high-dose inhaled corticosteroids and long-acting β₂-agonists.

Main Methods:

• A randomized, double-blind, crossover study design.
• Three 8-week treatment periods comparing tiotropium (5 μg, 10 μg) with placebo.
• Primary endpoint: peak FEV₁ at the end of each treatment period.

Main Results:

• Both 5 μg and 10 μg of tiotropium significantly increased peak FEV₁ compared to placebo (P < .0001).
• Tiotropium also improved trough FEV₁ and daily peak expiratory flow.
• No significant differences in asthma health status or symptoms; dry mouth was more frequent with 10 μg.

Conclusions:

• Once-daily tiotropium significantly enhances lung function over 24 hours in severe, persistent asthma.
• Tiotropium is an effective add-on therapy for patients with inadequately controlled severe asthma.
• The study supports tiotropium's role in managing difficult-to-treat asthma.